Duchenne Muscular Dystrophy (DMD) Therapeutics - Global Top Players Market Share and Ranking 2025- YH Research

Home > Reports >Medical Care > Duchenne Muscular Dystrophy (DMD) Therapeutics - Global Top Players Market Share and Ranking 2025

Duchenne Muscular Dystrophy (DMD) Therapeutics - Global Top Players Market Share and Ranking 2025

Publication Date: 2025-11-28
Report Id: 2856460
Industry: Medical Care
Report Page: 93
Chart: 96

PDF Download

Publication Date: 2025-11-28
Report Id: 2856460
Industry: Medical Care
Report Page: 93
Chart: 96

PDF Download

A research report provider that focuses on identifying industry pain points and solving core problems for companies！

Table of Contents
Description
Table of Figures
Need a Quote?

1 Market Overview
1.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Definition
1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast
1.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast
1.4 Share of China Duchenne Muscular Dystrophy (DMD) Therapeutics Market with Respect to the Global Market
1.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size: China VS Global Growth Rate, 2020-2031
1.6 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
1.6.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
1.6.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
1.6.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
1.6.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Policy

2 Global Leading Players and Market Share
2.1 By Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics, Global Market Share by Company, 2020-2025
2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Participants, Market Position (Tier 1, Tier 2, and Tier 3)
2.3 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Concentration Ratio
2.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Mergers & Acquisitions, Expansion Plans
2.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Major Companies Product Type
2.6 Head Office and Area Served of Key Players

3 China Leading Players, Market Share and Ranking
3.1 By Revenue of Duchenne Muscular Dystrophy (DMD) Therapeutics, China Market Share by Company, 2020-2025
3.2 China Duchenne Muscular Dystrophy (DMD) Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Participants, Market Position (Tier 1, Tier 2, and Tier 3)

4 Industry Chain Analysis
4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain
4.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Upstream Analysis
4.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Core Raw Materials
4.2.2 Main Manufacturers of Duchenne Muscular Dystrophy (DMD) Therapeutics Core Raw Materials
4.3 Midstream Analysis
4.4 Downstream Analysis
4.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Production Mode
4.6 Duchenne Muscular Dystrophy (DMD) Therapeutics Procurement Model
4.7 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Sales Model and Sales Channels
4.7.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Model
4.7.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Typical Distributors

5 Sights by Type
5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Classification by Type
5.1.1 Exondys
5.1.2 Emflaza
5.1.3 Translarna
5.1.4 Others
5.2 by Type, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value & CAGR, 2020 VS 2024 VS 2031
5.3 by Type, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, 2020-2031

6 Sights by Product Form
6.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Classification by Product Form
6.1.1 Hormonal Drugs
6.1.2 Exon Skipping
6.1.3 Small Molecule Drugs
6.1.4 Others
6.2 by Product Form, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value & CAGR, 2020 VS 2024 VS 2031
6.3 by Product Form, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, 2020-2031

7 Sights by Sales Channels
7.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Classification by Sales Channels
7.1.1 Online Sales
7.1.2 Offline Sales
7.2 by Sales Channels, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value & CAGR, 2020 VS 2024 VS 2031
7.3 by Sales Channels, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, 2020-2031

8 Sights by Application
8.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application
8.1.1 Hospitals
8.1.2 Clinics
8.1.3 Home Care
8.2 by Application, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value & CAGR, 2020 VS 2024 VS 2031
8.3 by Application, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, 2020-2031

9 Sales Sights by Region
9.1 By Region, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, 2020 VS 2024 VS 2031
9.2 By Region, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, 2020-2031
9.3 North America
9.3.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size & Forecasts, 2020-2031
9.3.2 By Country, North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share
9.4 Europe
9.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size & Forecasts, 2020-2031
9.4.2 By Country, Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share
9.5 Asia Pacific
9.5.1 Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size & Forecasts, 2020-2031
9.5.2 By Country/Region, Asia Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share
9.6 South America
9.6.1 South AmericaDuchenne Muscular Dystrophy (DMD) Therapeutics Market Size & Forecasts, 2020-2031
9.6.2 By Country, South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size Market Share
9.7 Middle East & Africa

10 Sales Sights by Country Level
10.1 By Country, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size & CAGR, 2020 VS 2024 VS 2031
10.2 By Country, Global Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value, 2020-2031
10.3 United States
10.3.1 United States Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2020-2031
10.3.2 by Type, United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.3.3 by Application, United States Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.4 Europe
10.4.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2020-2031
10.4.2 by Type, Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.4.3 by Application, Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.5 China
10.5.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2020-2031
10.5.2 by Type, China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.5.3 by Application, China Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.6 Japan
10.6.1 Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2020-2031
10.6.2 by Type, Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.6.3 by Application, Japan Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.7 South Korea
10.7.1 South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2020-2031
10.7.2 by Type, South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.7.3 by Application, South Korea Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.8 Southeast Asia
10.8.1 Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2020-2031
10.8.2 by Type, Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.8.3 by Application, Southeast Asia Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.9 India
10.9.1 India Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2020-2031
10.9.2 by Type, India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.9.3 by Application, India Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.10 Middle East & Africa
10.10.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size, 2020-2031
10.10.2 by Type, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031
10.10.3 by Application, Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Consumption Value Market Share, 2024 VS 2031

11 Company Profile
11.1 Sarepta Therapeutics
11.1.1 Sarepta Therapeutics Company Information, Head Office, Market Area, and Industry Position
11.1.2 Sarepta Therapeutics Company Profile and Main Business
11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Models, Specifications, and Application
11.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin, 2020-2025
11.1.5 Sarepta Therapeutics Recent Developments
11.2 ReveraGen BioPharma
11.2.1 ReveraGen BioPharma Company Information, Head Office, Market Area, and Industry Position
11.2.2 ReveraGen BioPharma Company Profile and Main Business
11.2.3 ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Models, Specifications, and Application
11.2.4 ReveraGen BioPharma Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin, 2020-2025
11.2.5 ReveraGen BioPharma Recent Developments
11.3 Sperogenix
11.3.1 Sperogenix Company Information, Head Office, Market Area, and Industry Position
11.3.2 Sperogenix Company Profile and Main Business
11.3.3 Sperogenix Duchenne Muscular Dystrophy (DMD) Therapeutics Models, Specifications, and Application
11.3.4 Sperogenix Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin, 2020-2025
11.3.5 Sperogenix Recent Developments
11.4 ReveraGen BioPharma Inc .
11.4.1 ReveraGen BioPharma Inc . Company Information, Head Office, Market Area, and Industry Position
11.4.2 ReveraGen BioPharma Inc . Company Profile and Main Business
11.4.3 ReveraGen BioPharma Inc . Duchenne Muscular Dystrophy (DMD) Therapeutics Models, Specifications, and Application
11.4.4 ReveraGen BioPharma Inc . Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin, 2020-2025
11.4.5 ReveraGen BioPharma Inc . Recent Developments
11.5 Belief BioMed
11.5.1 Belief BioMed Company Information, Head Office, Market Area, and Industry Position
11.5.2 Belief BioMed Company Profile and Main Business
11.5.3 Belief BioMed Duchenne Muscular Dystrophy (DMD) Therapeutics Models, Specifications, and Application
11.5.4 Belief BioMed Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin, 2020-2025
11.5.5 Belief BioMed Recent Developments
11.6 PTC Therapeutics
11.6.1 PTC Therapeutics Company Information, Head Office, Market Area, and Industry Position
11.6.2 PTC Therapeutics Company Profile and Main Business
11.6.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Models, Specifications, and Application
11.6.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin, 2020-2025
11.6.5 PTC Therapeutics Recent Developments
11.7 Santhera Pharmaceuticals
11.7.1 Santhera Pharmaceuticals Company Information, Head Office, Market Area, and Industry Position
11.7.2 Santhera Pharmaceuticals Company Profile and Main Business
11.7.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Models, Specifications, and Application
11.7.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin, 2020-2025
11.7.5 Santhera Pharmaceuticals Recent Developments
11.8 Italfarmaco
11.8.1 Italfarmaco Company Information, Head Office, Market Area, and Industry Position
11.8.2 Italfarmaco Company Profile and Main Business
11.8.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Models, Specifications, and Application
11.8.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Gross Margin, 2020-2025
11.8.5 Italfarmaco Recent Developments

12 Conclusion

13 Appendix
13.1 Research Methodology
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Market Estimation Model
13.4 Disclaimer

According to YH Research, the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics should grow from US$ 2307 million in 2024 to US$ 4626 million by 2031, with a CAGR of 11.4% for the period of 2025-2031.

Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

Duchenne Muscular Dystrophy (DMD) Therapeutics

According to YH Research, the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics should grow from US$ 2307 million in 2024 to US$ 4626 million by 2031, with a CAGR of 11.4% for the period of 2025-2031.

Unit: US$ M

www.yhresearch.com

In-depth insight into market trends

The Duchenne muscular dystrophy (DMD) treatment market is primarily driven by the following factors:
I. Disease Burden and Unmet Needs
High Disability and Mortality Rates:
DMD is a progressive muscle wasting disease. Patients typically lose the ability to walk around age 10 and die from cardiopulmonary failure between the ages of 20 and 30. With approximately 300,000 cases worldwide and over 70,000 in China, the disease poses a significant social burden.

If a female carrier gives birth to a boy, there is a 50% chance that the child will inherit the disease, creating a high family genetic risk.

Limitations of Existing Treatments:
Current mainstream treatments, including corticosteroids (such as deflazacort) and topical exon-skipping drugs (such as Exondys 51), can only delay the disease, not cure it, and require long-term use with significant side effects.

There is a lack of universal treatments, which only cover specific gene mutation types (such as exon 51/53 skipping), limiting their applicable population. Improved Diagnosis Rate:
With improved medical infrastructure and urbanization, China's DMD diagnosis rate is expected to rise from approximately 30% in 2022 to over 50% in 2025, bringing more patients into the treatment-needing population.

II. R&D Progress and Pipeline Breakthroughs
Breakthroughs in Gene Therapy and Oligonucleotide Technologies:
Gene therapies, such as Sarepta's SRP-9001 (microdystrophin delivered via an AAVrh74 vector) and Faith Pharmaceuticals' BBM-D101 (engineered AAV vector), achieve long-term protein expression with a single dose. Clinical trials have shown a significant increase in the percentage of positive fibers.

Huida Gene's CRISPR-Cas12 gene editing therapy has entered clinical trials, targeting gene mutation repair.

Oligonucleotide therapies, including antisense oligonucleotides (ASOs) and next-generation peptide-coupled oligonucleotides (PPMOs), such as PepGen's PGN-EDO51 and Entrada's ENTR-601-44, enhance cellular uptake and lysosomal escape, improving efficacy and reducing dosage. Active Domestic R&D Pipeline:
Over 10 DMD drugs have entered clinical trials in China, including gene editing (such as Huida Gene's CRISPR-Cas12), AAV gene therapy (Jinwei Bio's JWK007), and mini-protein drugs (Faith Pharmaceuticals' BBM-D101). Some have received FDA orphan drug designation and are expected to be launched after 2026.

III. Policy Support and Optimized Payment Environment
Policy Support for Rare Diseases:
US: The DUX Act extends the market exclusivity period for DMD orphan drugs to 7.5 years, and the accelerated approval process shortens drug launch time by 34%.

China: DMD will be included in the second round of rare disease listings in 2024, promoting domestic R&D. Medical insurance coverage has expanded, with vamorolone included in the national medical insurance negotiations. The price of domestically produced gene therapies is expected to drop below 2 million yuan by 2026.

Improved Affordability:
North America: Commercial insurance companies (such as UnitedHealthcare) have prioritized DMD gene therapy reimbursement, with medical insurance coverage exceeding 80%. In Europe, reimbursement rates for products that pass HTA assessment exceed 80%, but product launches lag 9-15 months behind those in the US.

Asia-Pacific: Markets such as China, Japan, and South Korea are experiencing significant growth, with policies and capital jointly driving therapeutic accessibility.

The DMD therapy market is driven by disease severity, technological breakthroughs, and favorable policies. Gene editing and RNA therapies will dominate the future, but high costs and production capacity bottlenecks (such as AAV vector production) still need to be overcome. Companies need to focus on technological innovation and payment model optimization to address unmet medical needs.

This report studies and analyses global Duchenne Muscular Dystrophy (DMD) Therapeutics status and future trends, to help determine the Duchenne Muscular Dystrophy (DMD) Therapeutics market size of the total market opportunity by Type, by Application, by company, and by region & country. This report is a detailed and comprehensive analysis of the world market for Duchenne Muscular Dystrophy (DMD) Therapeutics, and provides market size (US$ million) and Year-over-Year growth, considering 2023 as the base year.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

To assess the competitive environment within the market including supplier revenue, market share, and company profiles.

Highlights
(1) Global Duchenne Muscular Dystrophy (DMD) Therapeutics market size, history data 2019-2024, and forecast data 2025 -2030, (US$ million)
(2) Global Duchenne Muscular Dystrophy (DMD) Therapeutics by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(3) China Duchenne Muscular Dystrophy (DMD) Therapeutics by company, revenue, market share and industry ranking 2019-2024, (US$ million)
(4) Global Duchenne Muscular Dystrophy (DMD) Therapeutics key consuming regions, consumption value and demand structure
(5) Duchenne Muscular Dystrophy (DMD) Therapeutics industry chains, upstream, midstream and downstream
Market segment by players, this report covers
    Sarepta Therapeutics
    ReveraGen BioPharma
    Sperogenix
    ReveraGen BioPharma Inc .
    Belief BioMed
    PTC Therapeutics
    Santhera Pharmaceuticals
    Italfarmaco

Market segment by Type, covers
    Exondys
    Emflaza
    Translarna
    Others

Market segment by Application, can be divided into
    Hospitals
    Clinics
    Home Care

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa
Report Includes:
Chapter 1: to describe Duchenne Muscular Dystrophy (DMD) Therapeutics product scope, global consumption value, China consumption value, development opportunities, challenges, trends, and policies.
Chapter 2: Global Duchenne Muscular Dystrophy (DMD) Therapeutics market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 3: China Duchenne Muscular Dystrophy (DMD) Therapeutics market share and ranking of major manufacturers, revenue, 2019-2024
Chapter 4: Duchenne Muscular Dystrophy (DMD) Therapeutics industry chain, upstream, medium-stream, and downstream.
Chapter 5: Segment by Type, consumption value, percent & CAGR, 2019-2030
Chapter 6: Segment by Application, consumption value, percent & CAGR, 2019-2030
Chapter 7: Segment in regional level, consumption value, percent & CAGR, 2019-2030
Chapter 8: Segment in country level, consumption value, percent & CAGR, 2019-2030
Chapter 9: Company profile, introducing the basic situation of the main companies in the market in detail, including product specifications, application, recent development, revenue, gross margin.
Chapter 10: Conclusions